Fig. 4 | Scientific Reports

Fig. 4

From: N7-methyladenosine-induced SLC7A7 serves as a prognostic biomarker in pan-cancer and promotes CRC progression in colorectal cancer

Fig. 4

SLC7A7 genomic alterations and genomic instability. (A) SLC7A7 SNV were analyzed for pan-cancer. (B) Evaluated the COSMIC database for mutation types in SLC7A7. (C) In colon cancer, the SLC7A7 Somatic Mutation Rate: is 1.23%. (D) Correlations of CNV with mRNA expression. (E) CNV percentage in each cancer and Survival difference between CNV groups. (F) Variation in gene mutation, Gain, and Loss of high and low SLC7A7 expression in colon cancer.

Back to article page